[go: up one dir, main page]

WO2004010942A3 - Substituted heterocyclic compounds as modulators of the ccr5 receptor - Google Patents

Substituted heterocyclic compounds as modulators of the ccr5 receptor Download PDF

Info

Publication number
WO2004010942A3
WO2004010942A3 PCT/US2003/023523 US0323523W WO2004010942A3 WO 2004010942 A3 WO2004010942 A3 WO 2004010942A3 US 0323523 W US0323523 W US 0323523W WO 2004010942 A3 WO2004010942 A3 WO 2004010942A3
Authority
WO
WIPO (PCT)
Prior art keywords
ccr5
receptor
modulators
substituted heterocyclic
heterocyclic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/023523
Other languages
French (fr)
Other versions
WO2004010942A2 (en
Inventor
William E Bondinell
Michael J Neeb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to AU2003256922A priority Critical patent/AU2003256922A1/en
Publication of WO2004010942A2 publication Critical patent/WO2004010942A2/en
Publication of WO2004010942A3 publication Critical patent/WO2004010942A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to substituted heterocyclic compounds which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, all in mammals, by the use of substituted heterocyclic compounds which are CCR5 receptor antagonists. Furthermore, since CD8+ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.
PCT/US2003/023523 2002-07-31 2003-07-28 Substituted heterocyclic compounds as modulators of the ccr5 receptor Ceased WO2004010942A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003256922A AU2003256922A1 (en) 2002-07-31 2003-07-28 Substituted heterocyclic compounds as modulators of the ccr5 receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40025602P 2002-07-31 2002-07-31
US60/400,256 2002-07-31

Publications (2)

Publication Number Publication Date
WO2004010942A2 WO2004010942A2 (en) 2004-02-05
WO2004010942A3 true WO2004010942A3 (en) 2004-07-08

Family

ID=31188673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/023523 Ceased WO2004010942A2 (en) 2002-07-31 2003-07-28 Substituted heterocyclic compounds as modulators of the ccr5 receptor

Country Status (2)

Country Link
AU (1) AU2003256922A1 (en)
WO (1) WO2004010942A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889690B2 (en) 2007-04-27 2014-11-18 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
JP2008501031A (en) 2004-05-28 2008-01-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド Muscarinic receptor modulators
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP2008510728A (en) 2004-08-19 2008-04-10 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
US7863449B2 (en) 2004-11-29 2011-01-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1988892A2 (en) 2006-02-22 2008-11-12 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN101500565A (en) 2006-06-29 2009-08-05 弗特克斯药品有限公司 Modulators of muscarinic receptors
EP2575815A4 (en) 2010-06-04 2013-12-25 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
EP2864322B1 (en) 2012-06-20 2016-04-27 Novartis AG Complement pathway modulators and uses thereof
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
WO2015168286A1 (en) 2014-04-30 2015-11-05 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparaiton and use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005819A1 (en) * 2000-07-15 2002-01-24 Smithkline Beecham Corporation Compounds and methods
WO2002016351A1 (en) * 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Quinazoline derivatives as kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005819A1 (en) * 2000-07-15 2002-01-24 Smithkline Beecham Corporation Compounds and methods
WO2002016351A1 (en) * 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Quinazoline derivatives as kinase inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889690B2 (en) 2007-04-27 2014-11-18 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9365563B2 (en) 2007-04-27 2016-06-14 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof

Also Published As

Publication number Publication date
AU2003256922A1 (en) 2004-02-16
WO2004010942A2 (en) 2004-02-05
AU2003256922A8 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
WO2004011427A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
WO2004010942A3 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
WO2004010943A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
IL133730A0 (en) Compounds and methods substituted benzanilides as ccr5 ligands
AR013669A1 (en) COMPOUNDS AND METHODS
EP1140072A4 (en) Compounds and methods
TW200608995A (en) Antagonizing interleukin-21 receptor activity
EP2276741B1 (en) Isoquinolinone derivatives as nk3 antagonists
DK1718649T3 (en) Imidazo [1,2-c] pyrimidinyleddikesyrederivater
ATE422496T1 (en) SUBSTITUTED PYRIDOÄ2,3-DÜPYRIMIDINE DERIVATIVES SUITABLE AS MEDICATIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO2007092681A3 (en) Piperidinyl derivatives as modulators of chemokine receptor activity
US20080139551A1 (en) Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
SG155943A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
ATE531711T1 (en) TETRAHYDROCYCLOPENTAÄBÜINDOL-3-YL CARBONIC ACID DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
WO2006069805A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
EP1156801A4 (en) COMPOS S AND M THODES
WO2002034760A3 (en) Compounds and methods
NO20071399L (en) VLA-4 antagonists
WO2006004924A3 (en) Imidazolo-related compounds, compositions and methods for their use
TW200745087A (en) CCR5 antagonists useful for treating HIV
WO2025006568A3 (en) Mk2 inhibitors and methods of making and using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP